Navigation Links
Atrium completes the sale of its Active Ingredients and Specialty Chemicals division
Date:5/22/2008

QUEBEC CITY, May 22 /PRNewswire-FirstCall/ - In accordance with the terms previously announced on April 4, 2008, Atrium Innovations Inc. "Atrium" (TSX: ATB) today announced that it has completed the sale of its Active Ingredients and Specialty Chemicals division for total proceeds of US$166.4 million in cash, subject to a post-closing working capital adjustment. Atrium is now a health and nutrition pure-play and the net proceeds from the transaction will provide the Company with better financial flexibility to pursue its corporate strategy.

About Atrium

Atrium Innovations Inc. is a recognized leading developer, manufacturer and marketer of science-based and professionally endorsed products for the health and nutrition industries. The Company focuses primarily on growing segments of the health and nutrition markets which are benefiting from the trends towards healthy living and the ageing of the population. Atrium markets a broad portfolio of finished products through its highly specialized sales and marketing network in more than 35 countries, primarily in North America and Europe. Atrium has over 575 employees and operates five manufacturing facilities. Additional information about Atrium is available on its Web site at http://www.atrium-innov.com.


'/>"/>
SOURCE Atrium Innovations Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Atrium Medical Receives FDA Approval for its Novel C-QUR Lite(TM) V-Patch and C-QUR Edge(TM) V-Patch
2. Atrium shows a strong financial performance for its first quarter
3. Atrium Innovations to Hold 2008 First Quarter Financial Results Conference Call and Webcast on May 6
4. Atrium Innovations to Hold 2007 Fourth Quarter and Full-Year Financial Results Conference Call and Webcast on February 29
5. Atrium Announces a Significant Increase in Revenues and Earnings for the Third Quarter of 2007
6. Atrium Innovations to Hold 2007 Third Quarter Financial Results Conference Call and Webcast on November 8
7. Atrium Innovations Announces Management Changes
8. Sangart, Inc. Completes Enrollment in Second Phase III Study of Hemospan, a Novel Oxygen Transport Agent
9. SynCo Bio Partners Completes Manufacture and Release of ActoGeniX Lead Product for Phase II Clinical Trials
10. Lilly Completes Final Phase of Its Indianapolis Biotechnology Complex
11. China-Biotics, Inc. Completes Foundation for Its New Plant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... , ... March 29, 2017 , ... Bactana Animal Health, ... in the world’s food supply through enhancement of the gut microbiota, today announced the ... Connecticut Innovations , New York-based Sustainable Income Capital Management, LLC and a number ...
(Date:3/29/2017)... -- Research and Markets has announced the addition ... report to their offering. ... The study scope includes key ... interference, synthetic biology tools and genome editing tools); synthetic biology-enabled ... technologies and products are analyzed to determine present and future ...
(Date:3/28/2017)... ... March 28, 2017 , ... Franz Inc ., the leading supplier ... has been named a ‘Champion’ by Bloor Research in its recent Graph Database ... its class, and, thanks to Gruff, it was rated as the easiest product to ...
(Date:3/28/2017)... WASHINGTON , March 28, 2017 /PRNewswire/ ... launch single-cell sequencing during the American Association for Cancer ... Convention Center in Washington, D.C. , ... differential gene expression of thousands of cells at the ... Experts on-hand at AACR to discuss ...
Breaking Biology Technology:
(Date:3/7/2017)... , March 7, 2017   HireVue , the ... global companies identify the best talent, faster, today announced ... Sales Officer (CSO) and Diana Kucer as ... out a seasoned executive team poised to drive continued growth ... on a year of record bookings in 2017. ...
(Date:3/2/2017)... Australia , March 2, 2017 Australian ... Ltd (ASX: CYP), has signed an agreement with ... from the Monash Biomedicine Discovery Institute and Department of ... to conduct a further preclinical study to support the ... treatment of asthma.  Asthma is a ...
(Date:2/27/2017)... , Feb. 27, 2017   Strategic Cyber ... announced it has led a $3.5 million investment in  ... platform. Strategic Cyber Ventures is DC based and is ... Hank Thomas . Ron Gula , also ... Ventures, also participated in this series A round of ...
Breaking Biology News(10 mins):